Yahoo
NasdaqCM - Delayed Quote USD

Alpha Tau Medical Ltd. (DRTS)

13.06 -0.17 (-1.28%)
At close: October 30 at 4:00:01 PM EDT
Trade DRTS on Coinbase
Chart Range Bar
Loading chart for DRTS
  • Previous Close 13.23
  • Open 12.85
  • Bid 9.21 x 200
  • Ask 16.48 x 200
  • Day's Range 12.74 - 13.15
  • 52 Week Range 3.43 - 15.79
  • Volume 475,222
  • Avg. Volume 529,467
  • Market Cap (intraday) 1.208B
  • Beta (5Y Monthly) 1.22
  • PE Ratio (TTM) --
  • EPS (TTM) -1.04
  • Earnings Date (est.) Nov 19, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 17.80
  • Zacks Rating Bearish

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

www.alphatau.com

121

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DRTS
163.84%
S&P 500 (^GSPC)
10.73%

1-Year Return

DRTS
223.27%
S&P 500 (^GSPC)
11.11%

3-Year Return

DRTS
289.85%
S&P 500 (^GSPC)
81.91%

5-Year Return

DRTS
31.52%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
0.0%

Analyst Insights

View More

Analyst Price Targets

8.00 Low
17.80 Average
13.06 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/20/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 16 -> 16

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    1.21B

  • Enterprise Value

    1.13B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    27.43

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.71%

  • Return on Equity (ttm)

    -141.68%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -92.57M

  • Diluted EPS (ttm)

    -1.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    100.64M

  • Total Debt/Equity (mrq)

    34.39%

  • Levered Free Cash Flow (ttm)

    -20.26M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

13.06 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: